Fundraising FoxParadigm Capital — Full Portfolio
4 tracked investments · listed companies and verified rows first
Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy.
BiotechDeep TechHealthtechBoston, US
Steve Petrou(Co-Founder, President of Research & Development)inKiran Reddy(Executive Officer, Director)inMarcio Souza(President & Chief Executive Officer)in
BoardNicholas G. Galakatos(Director)in
Co-investorsAvoro Capital AdvisorsCapria VenturesOCV PartnersAlameda ResearchAPOLLO PROJECTSBlackstone+6 more
Antares Industries develops nuclear reactor technology, with teams spanning nuclear, reactor hardware, and mission engineering as well as manufacturing and regulatory operations.
Advanced ManufacturingCleantechDeep TechDefense TechEnergyParker, US
Jordan Bramble(CEO & Co-Founder)inJulia DeWahl(Founder)inRian Bahran(Chief Nuclear Officer)inMark Massie(Chief Engineer)inDONALD G MACK(Executive Officer, Director)
BoardJack Altman(Director)
Co-investors53 StationsAtacama VenturesBalerion Space VenturesBoxGroupCaffeinated CapitalHeartfelt Capital+21 more
Compound provides wealth management technology and services enabling advisors to deliver personalized financial, tax, and investment planning for clients.
FintechSan Francisco, US
Jordan Gonen(Founder)inJacob Schein(Founder)inAlex Farman-Farmaian(Co-Founder & CEO)in
Co-investorsAltaIR CapitalEvolution VenturesMPG FundThink+ Ventures Management, LlcWayfinder VenturesXYZ Venture Capital+17 more
Praxis offers an alternative to traditional college for eligible U.S. citizens, providing a program focused on self-direction, practical job skills, and a supported job search with a job-offer guarantee.
EdTechFuture of Work
Co-investorsService Provider CapitalAlameda ResearchAPOLLO PROJECTSFirework VenturesNorwest Venture PartnersPenny Jar Capital Venture+5 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.